Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Sitemap: http://zytoprotec.com/sitemap.xml User-agent: * |
Title | Zytoprotec GMBH / |
Description | Advancing Peritoneal Dialysis Menu Advancing Peritoneal Dialysis (PD) Millions of patients worldwide depend on dialysis to survive. Our novel fluid, PDprotec ® , is designed to improve |
Keywords | N/A |
WebSite | zytoprotec.com |
Host IP | 193.81.82.82 |
Location | Austria |
Site | Rank |
US$289,166
Last updated: 2022-12-07 03:38:57
zytoprotec.com has Semrush global rank of 36,602,975. zytoprotec.com has an estimated worth of US$ 289,166, based on its estimated Ads revenue. zytoprotec.com receives approximately 33,366 unique visitors each day. Its web server is located in Austria, with IP address 193.81.82.82. According to SiteAdvisor, zytoprotec.com is safe to visit. |
Purchase/Sale Value | US$289,166 |
Daily Ads Revenue | US$267 |
Monthly Ads Revenue | US$8,008 |
Yearly Ads Revenue | US$96,092 |
Daily Unique Visitors | 2,225 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
zytoprotec.com. | A | 3599 | IP: 193.81.82.82 |
zytoprotec.com. | NS | 3600 | NS Record: dns3.a1.net. |
zytoprotec.com. | NS | 3600 | NS Record: dns1.a1.net. |
zytoprotec.com. | NS | 3600 | NS Record: dns2.a1.net. |
zytoprotec.com. | MX | 3600 | MX Record: 0 zytoprotec-com.mail.protection.outlook.com. |
zytoprotec.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
Menu Advancing Peritoneal Dialysis (PD) Millions of patients worldwide depend on dialysis to survive. Our novel fluid, PDprotec ® , is designed to improve the outcomes of this treatment and reduce the burden of kidney failure for patients and health care providers. PDprotec ® addresses the global market for PD-fluids (USD 3 billion) and has the potential to increase the share of PD in the overall dialysis market (USD 13 billion) > more information PDprotec ® – key advantages Ph I + II Outstanding safety & efficacy > read more Improved clinical outcome Prolonged time for which patients can benefit from PD Increase market share of PD in dialysis overall The Zytoprotec success story Beginning of Phase III Study > read more Product prepared to enter pivotal Phase III trial in 2021 Outstanding safety and efficacy demonstrated for PDprotec ® in Phase I/II and Phase II studies Orphan Drug designation granted by FDA Follow-on PD fluid ICOprotec™ ready for clinical development |
HTTP/1.1 200 OK Server: nginx Date: Wed, 13 Jul 2022 09:10:49 GMT Content-Type: text/html; charset=utf-8 Content-Length: 33626 Connection: keep-alive Cache-Control: must-revalidate, proxy-revalidate, private, no-cache, max-age=0 ETag: "3d80f99a2f8054d37ec7f85de3bea607" Cache-Control: max-age=2592000 Expires: Fri, 12 Aug 2022 09:10:49 GMT |
Domain Name: ZYTOPROTEC.COM Registry Domain ID: 783038302_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.ascio.com Registrar URL: http://www.ascio.com Updated Date: 2022-01-30T08:24:00Z Creation Date: 2007-01-29T16:47:16Z Registry Expiry Date: 2023-01-29T16:47:16Z Registrar: Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA Registrar IANA ID: 106 Registrar Abuse Contact Email: abuse@ascio.com Registrar Abuse Contact Phone: +1.4165350123 Domain Status: ok https://icann.org/epp#ok Name Server: DNS1.A1.NET Name Server: DNS2.A1.NET Name Server: DNS3.A1.NET DNSSEC: unsigned >>> Last update of whois database: 2022-07-13T09:18:03Z <<< |